This HTML5 document contains 37 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n8http://linked.opendata.cz/resource/drugbank/drug/DB03511/identifier/chebi/
n12http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n9http://linked.opendata.cz/resource/drugbank/drug/DB03511/identifier/pdb/
n7http://linked.opendata.cz/resource/drugbank/drug/DB03511/identifier/kegg-compound/
n11http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n6http://linked.opendata.cz/resource/drugbank/drug/DB03511/identifier/drugbank/

Statements

Subject Item
n2:DB03511
rdf:type
n3:Drug
n3:group
experimental
owl:sameAs
n11:DB03511 n12:DB03511
dcterms:title
Galacturonic Acid
adms:identifier
n6:DB03511 n7:C08348 n8:33830 n9:GTR
n3:synthesisReference
Fabrizio Ungarelli, Silvano Piani, "Process for the synthesis of glycosaminoglycans containing .alpha.-L-galacturonic acid substituted with nucleophilic groups in position 3." U.S. Patent US5410039, issued August, 1990.
n3:IUPAC-Name
n4:271B4F49-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4F4F-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4F4E-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4F4B-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4F4C-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4F4D-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4F47-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4F48-363D-11E5-9242-09173F13E4C5 n4:271B4F45-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4F46-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B4F55-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4F56-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4F50-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4F51-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4F53-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4F52-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4F54-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
14982-50-4
n3:Bioavailability
n4:271B4F5B-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4F5D-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4F5E-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4F5A-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4F59-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4F5C-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4F4A-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4F57-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4F58-363D-11E5-9242-09173F13E4C5